Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [(177)Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience

SIMPLE SUMMARY: In this study, we investigated co-medication with enzalutamide, a well-established newer androgen axis drug, as a potential re-sensitizer for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in n = 10 patients with imminent treatment failure on standard (1...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosar, Florian, Bader, Hanna, Bartholomä, Mark, Maus, Stephan, Burgard, Caroline, Linxweiler, Johannes, Khreish, Fadi, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179420/
https://www.ncbi.nlm.nih.gov/pubmed/35681671
http://dx.doi.org/10.3390/cancers14112691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179420/
https://www.ncbi.nlm.nih.gov/pubmed/35681671
http://dx.doi.org/10.3390/cancers14112691

Ejemplares similares